Secor Capital Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Secor Capital Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-30,337	Closed	-$312K	–	623
2016 Q4	$312K	Sell	30,337 -42,899	-59%	-$392K	0.04%	403
2016 Q3	$740K	Buy	+73,236	New	+$800K	0.08%	299
2015 Q4	–	Sell	-17,804	Closed	-$334K	–	668
2015 Q3	$334K	Buy	+17,804	New	+$303K	0.1%	327

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Secor Capital Advisors's CNCE Position: Q1 2017 in Review

Secor Capital Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017, closing a stake of 30,337 shares — an estimated $312K sold.

Secor Capital Advisors first reported a position in CNCE in Q3 2015 and held it in 3 quarters. The position peaked at $740K in Q3 2016. 85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

Secor Capital Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Secor Capital Advisors sold 30,337 Concert Pharmaceuticals, Inc. shares in Q1 2017, an estimated $312K.
Secor Capital Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
Secor Capital Advisors's Concert Pharmaceuticals, Inc. position peaked at $740K in Q3 2016.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on Secor Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.